• Signs the written informed consent form.

• Female participants who are at least 18 years of age on the day of signing informed consent with.

• ECOG of 0 or 1.

• Life expectancy ≥ 3 months.

• Histologically diagnosed high-grade epithelial ovarian cancer (including high-grade serous, clear cell, G3 endometrioid) that has relapsed after platinum-containing standard chemotherapy.

‣ Recurrence of Platinum-sensitive (relapse ≥6 months after the end of platinum-containing therapy) who is not suitable for platinum-containing therapy after ≥ 3 lines of therapy;

⁃ Recurrence of platinum resistance , ≤3 previous lines of therapy. Note: Ovarian cancer includes ovarian cancer, fallopian tube cancer and primary peritoneal cancer in this study, unless otherwise specified.

• Has measurable disease based on RECIST v1.1 as determined by the site study team.

• Be able to provide formalin fixed, paraffin-embedded (FFPE) tumor tissue.

• Has adequate organ function.

• All subjects of reproductive potential must agree to use an effective method of contraception, during and for 6 months after the last dose of study treatment.